Shengmeng Di

Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma

Min Yu, Hong Luo, Mingliang Fan et al. · Molecular Therapy · 2017 · 185 citations · Full text

Life Sciences, Immunology, Oncology +16

Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma

Xiuqi Wu, Hong Luo, Bizhi Shi et al. · Molecular Therapy · 2019 · 157 citations · Full text

Medicine, Oncology, Pharmacology +17

Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3–Targeted Chimeric Antigen Receptor–Engineered T Cells in Hepatocellular Carcinoma

Ying Liu, Shengmeng Di, Bizhi Shi et al. · The Journal of Immunology · 2019 · 140 citations

Medicine, Immunology, Oncology +17

Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice

Ruixin Sun, Hong Luo, Su Jingwen et al. · Molecular Therapy · 2020 · 120 citations · Full text

Medicine, Oncology, Pharmacology +17

Combined Adjuvant of Poly I:C Improves Antitumor Effects of CAR-T Cells

Shengmeng Di, Min Zhou, Zeyan Pan et al. · Frontiers in Oncology · 2019 · 84 citations · Full text

Life Sciences, Immunology, Oncology +17